• LAST PRICE
    0.5602
  • TODAY'S CHANGE (%)
    Trending Up0.0149 (2.7324%)
  • Bid / Lots
    0.5201/ 12
  • Ask / Lots
    0.5411/ 3
  • Open / Previous Close
    0.5420 / 0.5453
  • Day Range
    Low 0.5420
    High 0.6049
  • 52 Week Range
    Low 0.4320
    High 4.9500
  • Volume
    10,102
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.5453
TimeVolumeLIXT
09:57 ET12000.542
10:30 ET1000.542101
12:18 ET1000.604899
12:30 ET37950.5441
02:56 ET1000.5898
03:00 ET3010.5602
03:56 ET2000.5604
03:59 ET12430.5602
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesLIXT
Lixte Biotechnology Holdings Inc
9.8M
-1.2x
---
United StatesPHIO
Phio Pharmaceuticals Corp
8.1M
-0.6x
---
United StatesUNCY
Unicycive Therapeutics Inc
9.0M
-0.6x
---
United StatesPALI
Palisade Bio Inc
8.0M
0.3x
---
United StatesCWBR
CohBar Inc
8.6M
-0.6x
---
United StatesGLMD
Galmed Pharmaceuticals Ltd
8.3M
-0.3x
---
As of 2022-10-02

Company Information

Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two categories of compounds at various stages of pre-clinical and clinical development that has the therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The Company has developed two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. The LB-100 series consists of structures, which is treated not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which are useful for the treatment of chronic hereditary diseases.

Contact Information

Headquarters
No. 2, 248 Route 25AEAST SETAUKET, NY, United States 11733
Phone
310-203-2902
Fax
928-982-5050

Executives

Chairman of the Board, President, Chief Executive Officer, Chief Scientific Officer
John Kovach
Chief Financial Officer, Vice President
Robert Weingarten
Chief Administrative Officer
Eric Forman
Chief Medical Officer
James Miser
Director
Gil Schwartzberg

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$9.8M
Revenue (TTM)
$0.00
Shares Outstanding
16.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.81
EPS
$-0.45
Book Value
$0.35
P/E Ratio
-1.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.